![image008](https://s3.eu-west-3.amazonaws.com/perrigo.com/zephrex-d-com-assets/styles/thumbnail_medium/s3/inline-images/image008.png?VersionId=u0DWfege0PO8mh9Prn1Poa3EXJJqVl_2&itok=-b3alQMs)
The Tarex® Difference
Zephrex-D is Different
![image006](https://s3.eu-west-3.amazonaws.com/perrigo.com/zephrex-d-com-assets/styles/inline/s3/inline-images/image006%20%281%29.jpg?VersionId=YWPwLpj9GVHVS_NUA0AyfJjp1jvvZRjp&itok=IK8u5zwM)
Unlike other PSE decongestants, Zephrex-D contains the pharmacist-trusted pseudoephedrine you’ve come to rely on, but its unique meth-blocking technology makes it the only highly meth-resistant PSE on the market today.
Yes, It Makes A Real Difference
![image012](https://s3.eu-west-3.amazonaws.com/perrigo.com/zephrex-d-com-assets/styles/thumbnail/s3/inline-images/image012.png?VersionId=2qR8PzyqCOuWWC1TvMk5n0NGDdhN8E56&itok=cYP6EV8c)
Zephrex-D is the only nasal decongestant with patented Tarex®, which makes it virtually impossible to be converted into illegal methamphetamine using today’s known clandestine methods.
Which can mean:
-
Healthier communities
-
Lower crime rates
-
Safer for local law officers and first responders
Meth abuse is estimated to cost US taxpayers as much as $48.3 billion/year. These costs include, but are not limited to: law enforcement, uninsured burn victims, incarceration and rehabilitation of addicts, foster care for dependents, toxic waste cleanup and secondary meth crimes. More importantly, these costs are increasing, not diminishing.
![image004](https://s3.eu-west-3.amazonaws.com/perrigo.com/zephrex-d-com-assets/inline-images/image004.jpg?VersionId=3A_3_V1CC9wjbx.kf5RZGsbI19NgueUb)
Only Zephrex-D could not be converted into meth using the popular and dangerous one-pot method.
* One box is 30mg/pill x 24ct = 720 mg
** Based on Acura Pharmaceuticals Test Results published in The American Journal of Drug and Alcohol Abuse
*** Franklin County Narcotics Enforcement Unit Testing. November 2011